Highlights

  • ResMed reported Q3 FY2026 Revenue of US$1.4 billion, up 11% year-on-year, supported by strong device Demand.
  • Operating margins expanded significantly, with non-GAAP EPS rising to US$2.86.
  • The company generated US$554 million in Operating Cash Flow and returned Capital through dividends and share Buybacks.

 

ResMed Inc. (ASX:RMD) traded at 27.44 AUD, rising 3.53% in the latest session, outperforming the broader healthcare sector as represented by the S&P/ASX 200 Health Care index, which gained 3.0% during the same period.

The share price movement reflects continued investor confidence following strong quarterly Earnings and improving Margin performance. ResMed remains one of the key large-cap healthcare technology names in the ASX healthcare index, and its performance is closely tied to global demand for sleep apnea and respiratory care devices.

Q3 FY2026 Earnings Overview and Business Performance

ResMed reported revenue of US$1.4 billion for the third quarter of fiscal year 2026, representing 11% year-on-year growth, or 8% on a constant currency basis. The results were driven by sustained demand for its core portfolio of sleep apnea devices, masks, and accessories across major global markets.

Revenue growth was geographically balanced, with the Americas contributing a 9% increase excluding software services, while Europe, Asia, and other regions delivered 7% constant currency growth. Residential care software also contributed modest expansion, reinforcing ResMed’s diversified revenue base across hardware and digital health solutions.

The company’s performance reflects continued structural demand growth in sleep-disordered breathing diagnosis and treatment, supported by higher diagnosis rates and improved patient access to therapy solutions.

Margin Expansion and Operational Efficiency

A key feature of the quarter was significant gross margin expansion, with GAAP and non-GAAP gross margins increasing by 290 basis points to approximately 62%. This improvement was driven primarily by component cost reductions, Manufacturing efficiencies, and favorable product mix dynamics.

Operating Leverage was also evident in income from operations, which increased 17% on a GAAP basis and 18% on a non-GAAP basis. The margin expansion highlights the scalability of ResMed’s manufacturing and distribution model, where incremental revenue contributes disproportionately to operating profitability.

Selling, general, and administrative expenses increased due to Acquisition-related costs, employee expenses, and ongoing Investment in Marketing and technology infrastructure. However, as a percentage of revenue, these costs remained broadly stable, reflecting disciplined cost management relative to revenue expansion.

Earnings Per Share and Cash Flow Performance

Net Income for the quarter reached US$399 million, while Diluted Earnings per Share were US$2.74. On a non-GAAP basis, net income increased to US$417 million, with diluted EPS of US$2.86, representing a 21% increase year-on-year.

Operating cash flow was reported at US$554 million, exceeding net income for the period and indicating strong cash conversion efficiency. This level of cash generation supports both reinvestment in growth initiatives and Shareholder returns.

During the quarter, ResMed returned US$262 million to shareholders through a combination of dividends and share repurchases. This included US$175 million in buybacks and US$87 million in Dividend payments, reflecting a balanced capital allocation strategy.

Product Portfolio and Innovation Pipeline

ResMed continues to focus on its core sleep and respiratory care portfolio, including continuous positive airway pressure (CPAP) devices, masks, and digital health platforms.

Recent product launches, such as the AirTouch F30i Comfort full-face mask, demonstrate ongoing innovation within the mask segment, which is a key driver of Recurring Revenue. The company’s product ecosystem is designed to support long-term patient adherence, which is critical for sustained revenue generation in sleep apnea therapy markets.

In parallel, ResMed is expanding its residential care software capabilities, although this segment remains smaller compared to its core device business. The integration of hardware and software reflects a broader healthcare trend toward connected care and remote patient monitoring.

Geographic Expansion and Infrastructure Investment

The company announced expansion of its U.S. operations with a new distribution center in Indiana, scheduled to begin operations in 2027. This investment is aimed at strengthening Supply chain resilience and improving distribution efficiency across North America, which remains one of ResMed’s largest markets.

The expansion supports the company’s long-term strategy of aligning manufacturing and logistics capacity with growing demand, particularly in high-Volume markets where timely delivery of devices and consumables is critical to patient outcomes.

Market Drivers and Sector Context

ResMed’s performance is closely tied to structural healthcare demand trends, particularly rising diagnosis rates of sleep apnea and increased awareness of sleep health globally. The company’s sixth annual Global Sleep Survey, conducted across 30,000 respondents in 13 countries, highlights growing awareness of sleep disorders and increasing willingness among patients to seek treatment.

The healthcare technology sector has also benefited from defensive investor positioning amid broader macroeconomic uncertainty, with medical device companies attracting stable cash flow-oriented investment flows.

Within this environment, ResMed’s combination of recurring revenue, high-margin consumables, and digital health integration positions it as a key structural beneficiary of long-term healthcare demand trends.

Dividend Policy and Capital Management

The board declared a quarterly dividend of US$0.60 per share, reinforcing the company’s consistent shareholder return policy. The dividend is supported by strong cash flow generation and stable earnings performance.

The company’s capital allocation strategy continues to balance reinvestment in product development and infrastructure expansion with direct returns to shareholders through dividends and buybacks. This approach reflects confidence in sustained earnings generation capacity.

Balance Sheet Strength and Financial Position

ResMed’s financial position remains supported by strong operating cash flow and disciplined capital allocation. The company’s ability to consistently generate cash above net income highlights efficient Working Capital Management and scalable operational infrastructure.

While ongoing investments in acquisitions and infrastructure expansion increase short-term expenditure, these are aligned with Long-term Growth initiatives in both developed and emerging healthcare markets.

Outlook and Growth Trajectory

ResMed’s outlook remains anchored in continued growth in sleep disorder diagnosis and treatment adoption globally. Structural demand drivers, including aging populations and increased awareness of sleep health, continue to support long-term market expansion.

Operationally, the company is expected to benefit from ongoing efficiency improvements, scale advantages, and expansion of its digital health ecosystem. However, near-term performance will continue to be influenced by currency fluctuations, regional demand variability, and investment in growth initiatives.

Conclusion

ResMed Inc.’s third quarter FY2026 results reflect a combination of steady revenue growth, significant margin expansion, and strong cash flow generation. The company continues to demonstrate operational leverage across its global healthcare platform, supported by sustained demand in sleep and respiratory care markets. Capital returns through dividends and share buybacks reinforce financial strength, while ongoing infrastructure investment supports long-term distribution efficiency. Share performance reflects investor confidence in these fundamentals, although future outcomes will remain closely tied to global healthcare demand trends and execution in core device and software segments.